Compare Iris Energy Limited (IREN) vs Sanofi SA (SNY) Price & Performance

IREN trades at $40.20, up 19.57% in 24 hours but remains volatile amid a broader AI infrastructure stock sell-off. The stock shows a bearish technical signal with support at $31 and resistance at $36. Fundamentally, revenue grew to $501M in 2025 with a 20.88% net income margin, but recent quarters missed EPS expectations. The company is transitioning from Bitcoin mining to AI cloud services, with significant capital investment driving negative cash flow from investing activities.

Wall Street maintains a bullish stance with a $79.11 consensus price target and 71% buy ratings, citing IREN's AI infrastructure potential. However, execution risks, competitive pressures from Meta and peers, and recent earnings misses pose significant challenges. The stock's high valuation multiples (P/E 43.66) require flawless growth execution to justify current levels.

SNY trades at $43.97, down 1.55% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings of $1.10 per share, beating expectations, and maintains robust profitability with a 71.92% gross margin. Recent FDA approval for Sarclisa's subcutaneous formulation and expanded AI research collaboration with Aqemia highlight ongoing innovation. Cash flow from operations remains healthy at $10.75 billion for 2025, though net cash flow is minimal at $49 million.

SNY presents a balanced investment case with solid fundamentals and analyst support (44% buy ratings), but faces risks from EU antitrust probes and patent expiration concerns for key drug Dupixent. Valuation metrics appear reasonable with P/E of 19.81 and P/B of 1.29. The stock's outlook depends on successful drug pipeline execution and navigating regulatory challenges, with current price levels offering stability near support.